Scott Biller

Scott Biller is a seasoned professional with extensive experience in the biopharma sector. Currently a Board Member at OMass Therapeutics and ROME Therapeutics, and an Executive Venture Partner at GV since December 2021, Scott Biller focuses on identifying innovative investment opportunities. Additionally, Scott serves as a Board Observer at Gate Bioscience and a Board Member at Remix Therapeutics and Foghorn Therapeutics, Inc. Previous roles include membership on the Scientific Advisory Boards of Vividion and Agios Pharmaceuticals, as well as a strategic advisory position and Chief Scientific Officer at Agios Pharmaceuticals from 2010 to 2023. Scott's career commenced at Novartis Institutes for BioMedical Research, where significant contributions were made as Vice President of Global Discovery Chemistry. Academically, Scott completed a BS in Chemistry at the Massachusetts Institute of Technology, a PhD in Organic Chemistry from Caltech, and a postdoctoral fellowship at Columbia University.